Item 1. Financial Statements
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Condensed Consolidated Balance Sheets
|
|
|
|
|
|
(In thousands of U.S. dollars, except share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2021
|
|
As of December 31, 2020
|
|
Assets
|
(Unaudited)
|
|
(Audited)
|
|
Current assets
|
|
|
|
|
Cash and cash equivalents
|
$
|
1,024,450
|
|
|
$
|
1,078,023
|
|
|
Short-term investments
|
214,925
|
|
|
211,766
|
|
|
Accounts receivable, net(i)
|
6,997
|
|
|
8,928
|
|
|
Other receivables
|
3,796
|
|
|
10,033
|
|
|
Current portion of loans receivable, net (ii)
|
6,717
|
|
|
7,083
|
|
|
Prepaids and other current assets
|
15,053
|
|
|
11,161
|
|
|
Inventory, net
|
46,437
|
|
|
44,002
|
|
|
Held-for-sale assets
|
1,969
|
|
|
1,176
|
|
|
Total current assets
|
1,320,344
|
|
|
1,372,172
|
|
|
Advances to joint ventures
|
487
|
|
|
467
|
|
|
Investments in equity accounted investees, net
|
19,221
|
|
|
19,235
|
|
|
Loan receivable, net (ii)
|
90,953
|
|
|
87,191
|
|
|
Property, plant and equipment, net
|
192,123
|
|
|
187,599
|
|
|
Right-of-use assets
|
8,538
|
|
|
9,776
|
|
|
Intangible assets, net
|
70,085
|
|
|
69,720
|
|
|
Goodwill
|
179,531
|
|
|
179,522
|
|
|
Total assets
|
$
|
1,881,282
|
|
|
$
|
1,925,682
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
Current liabilities
|
|
|
|
|
Accounts payable and other liabilities
|
$
|
29,213
|
|
|
$
|
42,102
|
|
|
Current portion of lease obligation
|
1,130
|
|
|
1,322
|
|
|
Derivative liabilities
|
272,300
|
|
|
163,410
|
|
|
Total current liabilities
|
302,643
|
|
|
206,834
|
|
|
Due to non-controlling interests
|
2,129
|
|
|
2,188
|
|
|
Lease obligation
|
8,231
|
|
|
8,492
|
|
|
|
|
|
|
|
Total liabilities
|
313,003
|
|
|
217,514
|
|
|
Commitments and contingencies(iii)
|
|
|
|
|
|
|
|
|
|
Shareholders’ equity
|
|
|
|
|
Share capital(iv, v)
|
584,912
|
|
|
569,260
|
|
|
Additional paid-in capital
|
32,090
|
|
|
34,596
|
|
|
Retained earnings
|
895,503
|
|
|
1,064,509
|
|
|
Accumulated other comprehensive income
|
58,144
|
|
|
42,999
|
|
|
Total equity attributable to shareholders of Cronos Group
|
1,570,649
|
|
|
1,711,364
|
|
|
Non-controlling interests
|
(2,370)
|
|
|
(3,196)
|
|
|
Total shareholders’ equity
|
1,568,279
|
|
|
1,708,168
|
|
|
Total liabilities and shareholders’ equity
|
$
|
1,881,282
|
|
|
$
|
1,925,682
|
|
(i)Net of current expected credit loss allowance on accounts receivable of $66 and $74 as of March 31, 2021 and December 31, 2020, respectively.
(ii)Net of current expected credit loss allowance on loans receivable of $3,020 and $2,439 as of March 31, 2021 and December 31, 2020, respectively.
(iii)Refer to Note 9. Commitments and Contingencies in the notes to condensed consolidated financial statements.
(iv)Authorized for issuance as of March 31, 2021: unlimited and December 31, 2020: unlimited.
(v)Shares issued as of March 31, 2021: 371,656,590 and December 31, 2020: 360,253,332.
See notes to condensed consolidated financial statements.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
|
|
|
|
|
(In thousands of U.S dollars, except share and per share amounts, unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31,
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
|
|
|
|
Net revenue, before excise taxes
|
|
|
|
|
$
|
14,654
|
|
|
$
|
9,344
|
|
|
|
|
|
|
Excise taxes
|
|
|
|
|
(2,043)
|
|
|
(912)
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
12,611
|
|
|
8,432
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
15,574
|
|
|
6,946
|
|
|
|
|
|
|
Inventory write-down
|
|
|
|
|
—
|
|
|
7,962
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
|
|
(2,963)
|
|
|
(6,476)
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing
|
|
|
|
|
10,254
|
|
|
7,112
|
|
|
|
|
|
|
Research and development (“R&D”)
|
|
|
|
|
5,102
|
|
|
4,590
|
|
|
|
|
|
|
General and administrative
|
|
|
|
|
21,906
|
|
|
23,759
|
|
|
|
|
|
|
Share-based payments
|
|
|
|
|
2,499
|
|
|
2,436
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
735
|
|
|
687
|
|
|
|
|
|
|
Total operating expenses
|
|
|
|
|
40,496
|
|
|
38,584
|
|
|
|
|
|
|
Operating loss
|
|
|
|
|
(43,459)
|
|
|
(45,060)
|
|
|
|
|
|
|
Other income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income, net
|
|
|
|
|
2,329
|
|
|
7,751
|
|
|
|
|
|
|
Gain (loss) on revaluation of derivative liabilities
|
|
|
|
|
(116,874)
|
|
|
113,368
|
|
|
|
|
|
|
Impairment loss on property, plant and equipment and right-of-use assets
|
|
|
|
|
(1,741)
|
|
|
—
|
|
|
|
|
|
|
Other loss
|
|
|
|
|
(1,859)
|
|
|
(378)
|
|
|
|
|
|
|
Total other income (loss)
|
|
|
|
|
(118,145)
|
|
|
120,741
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from continuing operations
|
|
|
|
|
(161,604)
|
|
|
75,681
|
|
|
|
|
|
|
Loss from discontinued operations
|
|
|
|
|
(21)
|
|
|
—
|
|
|
|
|
|
|
Net income (loss)
|
|
|
|
|
$
|
(161,625)
|
|
|
$
|
75,681
|
|
|
|
|
|
|
Net income (loss) attributable to:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cronos Group
|
|
|
|
|
$
|
(161,312)
|
|
|
$
|
76,040
|
|
|
|
|
|
|
Non-controlling interests
|
|
|
|
|
(313)
|
|
|
(359)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(161,625)
|
|
|
$
|
75,681
|
|
|
|
|
|
|
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange gain (loss) on translation
|
|
|
|
|
$
|
16,284
|
|
|
$
|
(113,692)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other comprehensive income (loss)
|
|
|
|
|
16,284
|
|
|
(113,692)
|
|
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
$
|
(145,341)
|
|
|
$
|
(38,011)
|
|
|
|
|
|
|
Comprehensive income (loss) attributable to:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cronos Group
|
|
|
|
|
$
|
(146,167)
|
|
|
$
|
(37,675)
|
|
|
|
|
|
|
Non-controlling interests
|
|
|
|
|
826
|
|
|
(336)
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(145,341)
|
|
|
$
|
(38,011)
|
|
|
|
|
|
|
Net income (loss) per share(i)
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic - continuing operations
|
|
|
|
|
$
|
(0.44)
|
|
|
$
|
0.22
|
|
|
|
|
|
|
Diluted - continuing operations(ii)
|
|
|
|
|
(0.44)
|
|
|
0.20
|
|
|
|
|
|
|
Weighted average number of outstanding shares
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
|
363,012,740
|
|
|
348,817,472
|
|
|
|
|
|
|
Diluted(ii)
|
|
|
|
|
363,012,740
|
|
|
374,330,168
|
|
|
|
|
|
(i) For the three months ended March 31, 2021 and 2020, the Company reported a basic and diluted loss from discontinued operations of $0.00 per share and $0.00 per share and $0.00 per share and $0.00 per share, respectively. See Note 7. Earnings (Loss) per Share.
(ii) In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. See Note 7. Earnings (Loss) per Share.
See notes to condensed consolidated financial statements.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Condensed Consolidated Statements of Changes in Equity
|
|
|
|
|
|
(In thousands of U.S. dollars, except share amounts, unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares
|
|
Share capital
|
|
|
|
Additional paid-in capital
|
|
Retained earnings
|
|
Accumulated other comprehensive income (loss)
|
|
Non-controlling interests
|
|
Total shareholders’ equity
|
|
Balance as of January 1, 2021
|
360,253,332
|
|
|
$
|
569,260
|
|
|
|
|
$
|
34,596
|
|
|
$
|
1,064,509
|
|
|
$
|
42,999
|
|
|
$
|
(3,196)
|
|
|
$
|
1,708,168
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercised
|
7,832,859
|
|
|
1,161
|
|
|
|
|
(1,161)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Vesting of options
|
—
|
|
|
—
|
|
|
|
|
2,064
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,064
|
|
|
Options exercised
|
3,570,399
|
|
|
3,213
|
|
|
|
|
(3,203)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
10
|
|
|
Vesting of restricted share units
|
—
|
|
|
—
|
|
|
|
|
435
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
435
|
|
|
Withholding taxes paid on share-based awards
|
—
|
|
|
—
|
|
|
|
|
(979)
|
|
|
(7,694)
|
|
|
—
|
|
|
—
|
|
|
(8,673)
|
|
|
Vesting of common shares issued in connection with the use of certain publicity rights in brand development
|
—
|
|
|
—
|
|
|
|
|
338
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
338
|
|
|
Top-up rights exercised
|
—
|
|
|
11,278
|
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
11,278
|
|
|
Net income (loss)
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
(161,312)
|
|
|
—
|
|
|
(313)
|
|
|
(161,625)
|
|
|
Foreign exchange gain (loss) on translation
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
15,145
|
|
|
1,139
|
|
|
16,284
|
|
|
Balance as of March 31, 2021
|
371,656,590
|
|
|
$
|
584,912
|
|
|
|
|
$
|
32,090
|
|
|
$
|
895,503
|
|
|
$
|
58,144
|
|
|
$
|
(2,370)
|
|
|
$
|
1,568,279
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares
|
|
Share capital
|
|
|
|
Additional paid-in capital
|
|
Retained earnings
|
|
Accumulated other comprehensive income (loss)
|
|
Non-controlling interests
|
|
Total shareholders’ equity
|
|
Balance as of January 1, 2020
|
348,817,472
|
|
|
$
|
561,165
|
|
|
|
|
$
|
23,234
|
|
|
$
|
1,137,646
|
|
|
$
|
27,838
|
|
|
$
|
(853)
|
|
|
$
|
1,749,030
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of options
|
—
|
|
|
—
|
|
|
|
|
1,730
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,730
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vesting of restricted share units
|
—
|
|
|
—
|
|
|
|
|
706
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
706
|
|
|
Vesting of common shares issued in connection with the use of certain publicity rights in brand development
|
—
|
|
|
2,000
|
|
|
|
|
(187)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,813
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
76,040
|
|
|
—
|
|
|
(359)
|
|
|
75,681
|
|
|
Foreign exchange gain (loss) on translation
|
—
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
(113,715)
|
|
|
23
|
|
|
(113,692)
|
|
|
Balance as of March 31, 2020
|
348,817,472
|
|
|
$
|
563,165
|
|
|
|
|
$
|
25,483
|
|
|
$
|
1,213,686
|
|
|
$
|
(85,877)
|
|
|
$
|
(1,189)
|
|
|
$
|
1,715,268
|
|
See notes to condensed consolidated financial statements.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Condensed Consolidated Statements of Cash Flows
|
|
|
|
|
|
(In thousands of U.S. dollars, except share amounts, unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31,
|
|
|
2021
|
|
2020
|
|
Operating activities
|
|
|
|
|
Net income (loss)
|
$
|
(161,625)
|
|
|
$
|
75,681
|
|
|
Items not affecting cash:
|
|
|
|
|
Inventory write-down
|
—
|
|
|
7,962
|
|
|
Share-based payments
|
2,499
|
|
|
2,436
|
|
|
Depreciation and amortization
|
1,880
|
|
|
1,162
|
|
|
Gain (loss) on revaluation of derivative liabilities
|
116,874
|
|
|
(113,368)
|
|
|
Impairment loss on property, plant and equipment and right-of-use assets
|
1,741
|
|
|
—
|
|
|
Expected credit losses on financial assets and non-cash charges to inventory
|
681
|
|
|
2,068
|
|
|
Other non-cash operating activities, net
|
1,749
|
|
|
643
|
|
|
Changes in non-cash working capital:
|
|
|
|
|
Accounts receivable, net
|
1,931
|
|
|
472
|
|
|
Other receivables
|
5,687
|
|
|
(1,235)
|
|
|
Prepaids and other current assets
|
(3,737)
|
|
|
(2,439)
|
|
|
Inventory, net
|
(1,007)
|
|
|
(14,319)
|
|
|
Accounts payable and other liabilities
|
(12,675)
|
|
|
2,039
|
|
|
Cash flows used in operating activities
|
(46,002)
|
|
|
(38,898)
|
|
|
Investing activities
|
|
|
|
|
Proceeds from (purchase of) short-term investments, net
|
—
|
|
|
80,333
|
|
|
Purchase of property, plant and equipment
|
(6,680)
|
|
|
(6,411)
|
|
|
Purchase of intangible assets
|
(392)
|
|
|
(1,105)
|
|
|
Advances on loans receivable
|
(2,645)
|
|
|
(14,512)
|
|
|
Other non-cash investing activities, net
|
—
|
|
|
781
|
|
|
Cash flows provided by (used in) investing activities
|
(9,717)
|
|
|
59,086
|
|
|
Financing activities
|
|
|
|
|
Repayment of lease obligations
|
(613)
|
|
|
(448)
|
|
|
Withholding taxes paid on share-based awards
|
(8,673)
|
|
|
—
|
|
|
Other non-cash investing activities, net
|
10
|
|
|
—
|
|
|
Cash flows provided by (used in) financing activities
|
(9,276)
|
|
|
(448)
|
|
|
Effect of foreign currency translation on cash and cash equivalents
|
11,422
|
|
|
(91,037)
|
|
|
Net change in cash and cash equivalents
|
(53,573)
|
|
|
(71,297)
|
|
|
Cash and cash equivalents, beginning of period
|
1,078,023
|
|
|
1,199,693
|
|
|
Cash and cash equivalents, end of period
|
$
|
1,024,450
|
|
|
$
|
1,128,396
|
|
|
Supplemental cash flow information
|
|
|
|
|
Interest paid
|
$
|
—
|
|
|
$
|
7
|
|
|
Interest received
|
1,157
|
|
|
7,758
|
|
|
Income taxes paid
|
624
|
|
|
—
|
|
See notes to condensed consolidated financial statements.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
1. Background, Basis of Presentation and Accounting Policies
(a)Background
Cronos Group Inc. (“Cronos Group” or the “Company”) is incorporated in the Province of British Columbia and under the Business Corporations Act (British Columbia) with principal executive offices at 111 Peter Street, Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.”
Cronos Group is an innovative global cannabinoid company, with international production and distribution across five continents. The Company is committed to building disruptive intellectual property by advancing cannabis research, technology and product development and is seeking to build an iconic brand portfolio. Cronos Group’s brand portfolio includes PEACE NATURALS™, a global wellness platform; two adult-use brands, COVE™ and Spinach™; and three U.S. hemp-derived consumer products brands, Lord Jones™, Happy Dance™ and PEACE+™.
Cronos Group has established strategic joint ventures in Canada, Israel, and Colombia. Cronos Israel (as defined herein) is consolidated for financial reporting purposes. The Company also holds approximately 31% of the issued capital of Cronos Australia Limited (“Cronos Australia”) and accounts for its investment in Cronos Australia under the equity method of accounting. For additional discussion regarding the joint ventures and strategic investment, see Note 3. Investments in Equity Accounted Investees, net.
(b)Out-of-period adjustments
The Company identified an error in the accounting related to the withholding taxes on the net exercise of stock options, which resulted in an understatement of accounts payable and other liabilities of $966 and overstatements of other receivables, retained earnings and common stock of $3,202, $3,838 and $330, respectively, as of December 31, 2020. The error was deemed immaterial, and thus the Company has recorded an out-of-period adjustment to the condensed consolidated balance sheet and the condensed consolidated statement of changes in equity as of March 31, 2021 to correct the error. This error had no impact to the condensed consolidated statement of net income (loss) and comprehensive income (loss). The impact of the out-of-period adjustments are included within the changes in non-cash working capital and withholding taxes paid on share-based awards lines in the Company’s condensed consolidated statements of cash flows.
(c)Basis of presentation
The interim condensed consolidated financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for any other reporting period.
These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2020 (the “Annual Financial Statements”).
Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated financial statements. These reclassifications had no effect on the reported results of operations and ending shareholder’s equity.
(d)Adoption of new accounting pronouncements
On January 1, 2021, the Company adopted ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU No. 2020-01”). ASU No. 2020-01 clarifies the interaction of accounting for the transition into and out of the equity method as well as measuring certain purchased options and forwards contracts to acquire investments. The adoption of ASU No. 2020-01 did not have an impact on the Company’s interim condensed consolidated financial statements.
On January 1, 2021, the Company adopted ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU No. 2019-12”). ASU No. 2019-12 eliminates certain exceptions and simplifies the application of U.S. GAAP-related changes in enacted tax laws or rates and employee stock option plans. The adoption of ASU No. 2019-12 did not have an impact on the Company’s interim condensed consolidated financial statements.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
(e)New accounting pronouncements not yet adopted
In August 2020, the FASB issued ASU 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging –Contracts in Entity’s Own Equity (Subtopic 815–40) (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. ASU No. 2020-06 is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. ASU No. 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU No. 2020-06 will have on its interim condensed consolidated financial statements.
2. Inventory, net
Inventory, net is comprised of the following items:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2021
|
|
As of December 31, 2020
|
|
Raw materials, net
|
|
$
|
11,182
|
|
|
$
|
11,489
|
|
|
Work-in-progress – dry cannabis, net
|
|
21,590
|
|
|
20,520
|
|
|
Work-in-progress – cannabis extracts, net
|
|
5,036
|
|
|
5,758
|
|
|
Finished goods – dry cannabis, net
|
|
5,677
|
|
|
4,894
|
|
|
Finished goods – cannabis extracts, net
|
|
2,141
|
|
|
1,011
|
|
|
Supplies and consumables
|
|
811
|
|
|
330
|
|
|
Total
|
|
$
|
46,437
|
|
|
$
|
44,002
|
|
Inventory is written down for any obsolescence such as slow-moving or non-marketable products, or when the net realizable value of inventory is less than the carrying value. For the three months ended March 31, 2021 and 2020, the Company recorded write-downs related to inventory of $nil and $7,962, respectively.
3. Investments in Equity Accounted Investees, net
The Company holds variable interests in Cronos Growing Company Inc. (“Cronos GrowCo”), Natuera S.à.r.l (“Natuera”), MedMen Canada Inc. (“MedMen Canada”) and Cannasoul Lab Services Ltd. (“CLS”).
Cronos GrowCo is a joint venture incorporated under the Canada Business Corporations Act (“CBCA”) on June 14, 2018 with the objective of cultivating and commercializing cannabis and cannabis products. Cronos Group holds variable interests in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt. Cronos GrowCo’s economic performance is driven by the quantity and strains of cannabis grown. The joint venture partners mutually determine the quantity and strains of cannabis grown.
MedMen Canada is a joint venture incorporated under the CBCA on March 13, 2018, with the objective of the retail sale and marketing of cannabis products in Canada. MedMen Canada holds the exclusive license to the MedMen brand in Canada for a minimum term of 20 years. Cronos holds variable interests in MedMen Canada through its ownership of 50% of MedMen Canada’s common shares and other subordinated debt. MedMen Canada’s economic performance is driven by the quantity and strains of cannabis sold. Subject to applicable law, the joint venture partners mutually determine the quantity and strains of cannabis to be sold in MedMen Canada’s retail stores, if and when stores are opened.
Natuera is a joint venture registered in Luxembourg with the objective of cultivating and commercializing hemp and cannabis products. Cronos holds variable interests in Natuera through its ownership of 50% of Natuera’s common shares and other debt. Natuera’s economic performance is driven by the quantity and strains of cannabis grown, which is mutually determined by the joint venture partners.
The Company’s investments in Cronos GrowCo, Natuera and MedMen Canada are exposed to economic variability from each entity’s performance; however, the Company does not consolidate the entities as it does not have the power to direct the activities that most significantly impact each entity’s economic performance. Thus, Cronos Group is not considered the primary beneficiary of each entity. These investments are accounted for as equity method investments classified as “Investments in equity accounted investees, net” in the consolidated balance sheets.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
CLS is a wholly owned subsidiary of Cannasoul Analytics Ltd., incorporated with the purpose of establishing a commercial cannabis analytical testing laboratory located on the premises of Cronos Israel (the “Cannasoul Collaboration”). Cronos Israel agreed to advance up to ILS 8,297 ($2,483) by a non-recourse loan to CLS over a period of two years from April 1, 2020 for the capital and operating expenditures of the laboratory. The loan bears interest at 3.5% annually. Cronos Israel will receive 70% of the profits of the laboratory until such time as it has recovered 150% of the amounts advanced to CLS, after which time it will receive 50% of the laboratory profits. As a result, the Company is exposed to economic variability from CLS’s performance. The Company does not consolidate CLS as it does not have the power to direct the activities that most significantly impact the entity’s economic performance; thus, the Company is not considered the primary beneficiary of the entity. The carrying amount of the non-recourse loan is recorded under loans receivable and the full loan amount, ILS 8,297, represents the Company’s maximum potential exposure to losses through the Cannasoul Collaboration. See Note 4. Loans Receivable, net for further information regarding loans receivable.
A reconciliation of the carrying amount of the investments in associates and joint ventures is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ownership interest
|
|
As of March 31, 2021
|
|
As of December 31, 2020
|
|
Cronos Australia
|
31%
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Cronos GrowCo
|
50%
|
|
$
|
19,221
|
|
|
$
|
19,235
|
|
|
Natuera
|
50%
|
|
—
|
|
|
—
|
|
|
|
|
|
$
|
19,221
|
|
|
$
|
19,235
|
|
The Company’s share of net earnings (losses) from equity investments accounted for under the equity method of accounting:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended March 31,
|
|
|
|
|
|
|
2021
|
|
2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cronos GrowCo
|
|
|
|
|
$
|
(299)
|
|
|
$
|
(311)
|
|
|
|
|
|
|
|
|
|
|
|
Natuera(i)
|
|
|
|
|
(1,344)
|
|
|
(861)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(1,643)
|
|
|
$
|
(1,172)
|
|
(i) The Company’s share of accumulated net losses in excess of its equity investment in Natuera has been applied as a loss allowance on the loan receivable. See Note 4. Loans Receivable, net.
The Company determined that the maximum exposure of loss on investments in non-consolidated investments is limited to the Company’s initial investment, advances and/or loans for each variable interest entity. The following is a summary of the maximum exposure to loss as of March 31, 2021 and December 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ownership interest
|
|
|
As of March 31, 2021
|
|
|
|
As of December 31, 2020
|
|
Cronos Australia
|
31%
|
|
|
|
$
|
1,553
|
|
|
|
|
$
|
1,530
|
|
|
Cronos GrowCo
|
50%
|
|
|
|
21,433
|
|
|
|
|
21,125
|
|
|
MedMen Canada
|
50%
|
|
|
|
487
|
|
|
|
|
467
|
|
|
Natuera
|
50%
|
|
|
|
8,160
|
|
|
|
|
8,154
|
|
|
Total
|
|
|
|
|
$
|
31,633
|
|
|
|
|
$
|
31,276
|
|
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
4. Loans Receivable, net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2021
|
|
As of December 31, 2020
|
|
Natuera Series A loan(i)
|
|
$
|
2,013
|
|
|
$
|
3,518
|
|
|
GrowCo Facility(ii)
|
|
796
|
|
|
3,137
|
|
|
Add: Accrued interest
|
|
3,908
|
|
|
428
|
|
|
Total current portion of loans receivable
|
|
6,717
|
|
|
7,083
|
|
|
GrowCo Facility(ii)
|
|
76,043
|
|
|
69,939
|
|
|
Mucci promissory note(iii)
|
|
13,654
|
|
|
13,324
|
|
|
Cannasoul collaboration loan(iv)
|
|
1,215
|
|
|
1,261
|
|
|
Add: Accrued interest
|
|
41
|
|
|
2,667
|
|
|
Total long-term portion of loans receivable
|
|
90,953
|
|
|
87,191
|
|
|
Total loans receivable, net
|
|
$
|
97,670
|
|
|
$
|
94,274
|
|
(i)As of March 31, 2021 and December 31, 2020, a current expected credit loss allowance of $1,151 and $685, respectively, was recorded against the master loan agreement entered into with Natuera on September 27, 2019 (the “Series A loan”). As of March 31, 2021 and December 31, 2020, a loss allowance of $4,582 and $3,024, respectively, was recorded against the Series A Loan related to the Company’s share of net loss from Natuera in excess of the carrying value of the equity method investment. Refer to Note 3 and Note 14.
(ii)As of March 31, 2021 and December 31, 2020, Cronos GrowCo had drawn C$98,500 ($78,405) and C$95,150 ($74,626), respectively, from a credit agreement it entered into with the Company in August 2019 (the “GrowCo Facility”). As of March 31, 2021 and December 31, 2020, a current expected credit loss allowance of $1,569 and $1,470, respectively, was recorded against the GrowCo Facility.
(iii)As of March 31, 2021 and December 31, 2020, a current expected credit loss allowance of $274 and $259, respectively, was recorded against the Mucci promissory note.
(iv)As of March 31, 2021 and December 31, 2020 CLS has received ILS 4,149 (approximately $1,241) from a non-recourse loan. As of March 31, 2021 and December 31, 2020 a current expected credit loss allowance of $26 and $25, respectively, was recorded against the Cannasoul collaboration loan.
5. Derivative Liabilities
On March 8, 2019, the Company closed the previously announced investment in the Company (the “Altria Investment”) by Altria Group, Inc. (“Altria”), pursuant to a subscription agreement dated December 7, 2018. As of the closing date of the Altria Investment, the Altria Investment consisted of 149,831,154 common shares of the Company and one warrant of the Company (the “Altria Warrant”), all of which were issued to a wholly owned subsidiary of Altria. As of the closing date of the Altria Investment, Altria beneficially held an approximately 45% ownership interest in the Company (calculated on a non-diluted basis). As summarized in this note, if exercised in full on such date, the exercise of the Altria Warrant would have resulted in Altria holding a total ownership interest in the Company of approximately 55% (calculated on a non-diluted basis). Pursuant to the investor rights agreement between the Company and Altria, entered into in connection with the closing of the Altria Investment (the “Investor Rights Agreement”), the Company granted Altria certain rights, among others, summarized in this note.
The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights Agreement and the Altria Warrant, as applicable.
a.The Altria Warrant entitles the holder, subject to certain qualifications and limitations, to subscribe for and purchase up to an additional 10% of the common shares of Cronos (approximately 82.6 million common shares at March 31, 2021) at a per share exercise price of C$19.00, which expires on March 8, 2023.
b.The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the R&D partnership with Ginkgo Bioworks Inc. (“Ginkgo”) (the “Ginkgo Strategic Partnership”)), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance. The price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Strategic Partnership will be C$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
c.In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”).
The price per common share to be paid by Altria pursuant to the exercise of its Top-up Rights will be, subject to certain limited exceptions, the 10-day volume-weighted average price of the common shares of the Company on the TSX for the ten full days preceding such exercise by Altria, provided that the price per common share of the Company to be paid by Altria pursuant to the exercise of its Top-up Rights in connection with the issuance of common shares of the Company pursuant to the exercise of options or warrants that were outstanding as of March 8, 2019 will be C$16.25 per common share without any set off, counterclaim, deduction, or withholding. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%. The Altria Warrant, Pre-emptive Rights, and fixed price Top-up Rights have been classified as derivative liabilities.
A reconciliation of the carrying amounts of the derivative liability for the three months ended March 31, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of January 1, 2021
|
|
Revaluation (gain)/loss
|
|
Exercise of rights
|
|
Foreign exchange effect
|
|
As of March 31, 2021
|
|
(a) Altria Warrant
|
$
|
138,858
|
|
|
$
|
92,964
|
|
|
$
|
—
|
|
|
$
|
2,834
|
|
|
$
|
234,656
|
|
|
(b) Pre-emptive Rights
|
12,095
|
|
|
7,833
|
|
|
—
|
|
|
245
|
|
|
20,173
|
|
|
(c) Top-up Rights
|
12,457
|
|
|
16,077
|
|
|
(11,278)
|
|
|
215
|
|
|
17,471
|
|
|
|
$
|
163,410
|
|
|
$
|
116,874
|
|
|
$
|
(11,278)
|
|
|
$
|
3,294
|
|
|
$
|
272,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of January 1, 2020
|
|
Revaluation (gain)/loss
|
|
Exercise of rights
|
|
Foreign exchange effect
|
|
As of March 31, 2020
|
|
(a) Altria Warrant
|
$
|
234,428
|
|
|
$
|
(88,104)
|
|
|
$
|
—
|
|
|
$
|
(13,958)
|
|
|
$
|
132,366
|
|
|
(b) Pre-emptive Rights
|
12,787
|
|
|
1,315
|
|
|
—
|
|
|
(1,032)
|
|
|
13,070
|
|
|
(c) Top-up Rights
|
49,945
|
|
|
(26,579)
|
|
|
—
|
|
|
(2,626)
|
|
|
20,740
|
|
|
|
$
|
297,160
|
|
|
$
|
(113,368)
|
|
|
$
|
—
|
|
|
$
|
(17,616)
|
|
|
$
|
166,176
|
|
Fluctuations in the Company’s share price are a primary driver for the changes in the derivative valuations during each reporting period. As the share price decreases for each of the related derivative instruments, the liability of the instrument generally decreases. Share price is one of the significant observable inputs used in the fair value measurement of each of the Company’s derivative instruments. During the three months ended March 31, 2021, the Company’s share price increased from December 31, 2020 resulting in a loss on revaluation of $116,874. During the three months ended March 31, 2020, the Company’s share price decreased from December 31, 2019 resulting in a gain on revaluation of $113,368.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
The fair values of the derivative liabilities were determined using the Black-Scholes pricing model as of March 31, 2021 and December 31, 2020 applying the following inputs:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2021
|
|
As of December 31, 2020
|
|
|
Altria Warrant
|
|
Pre-emptive Rights
|
|
Top-up Rights
|
|
Altria Warrant
|
|
Pre-emptive Rights
|
|
Top-up Rights
|
|
Share price at valuation date (i)
|
$11.88
|
|
$11.88
|
|
$11.88
|
|
$8.84
|
|
$8.84
|
|
$8.84
|
|
Subscription price (i)
|
$19.00
|
|
$16.25
|
|
$16.25
|
|
$19.00
|
|
$16.25
|
|
$16.25
|
|
Weighted average risk-free interest rate (ii)
|
0.22%
|
|
0.17%
|
|
0.14%
|
|
0.21%
|
|
0.17%
|
|
0.13%
|
|
Weighted average expected life (iii)
|
1.93
|
|
1.25
|
|
0.72
|
|
2.18
|
|
1.50
|
|
0.98
|
|
Expected annualized volatility (iv)
|
82%
|
|
82%
|
|
82%
|
|
81%
|
|
81%
|
|
81%
|
|
Expected dividend yield
|
—%
|
|
—%
|
|
—%
|
|
—%
|
|
—%
|
|
—%
|
(i)Per share in C$.
(ii)The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of March 31, 2021 and December 31, 2020, the risk-free interest rate uses a range of approximately 0.09% to 0.86% and 0.10% to 0.39%, respectively, for the Pre-emptive Rights and Top-up Rights.
(iii)The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of March 31, 2021 and December 31, 2020, the expected life uses a range of approximately 0.25 year to 4.50 years and 0.50 year to 5.00 years, respectively.
(iv)Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company as of March 31, 2021. As of December 31, 2020, volatility was based on the blended historical volatility levels of the Company and peer companies.
The following table quantifies each of the significant inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management’s best estimate as of the respective dates. While a decrease in the inputs noted below would cause a decrease in the carrying value of the derivative liability, there would also be an equal but opposite impact on net income (loss) as of March 31, 2021.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase as of March 31, 2021
|
|
|
|
Altria Warrant
|
|
Pre-emptive Rights
|
|
Top-up Rights
|
|
Share price
|
|
$
|
42,479
|
|
|
$
|
4,133
|
|
|
$
|
4,376
|
|
|
Weighted average expected life
|
|
18,051
|
|
|
3,039
|
|
|
683
|
|
|
Expected annualized volatility
|
|
35,099
|
|
|
2,865
|
|
|
2,785
|
|
These inputs are classified in Level 3 on the fair value hierarchy and are subject to volatility and several factors outside of the Company’s control, which could significantly affect the fair value of these derivative liabilities in future periods.
6. Share-based Payments
(a)Share-based award plans
The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans.
The following table summarizes the total stock-based compensation expense associated with the Company’s stock options and RSUs for the three months ended March 31, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended March 31,
|
|
|
|
2021
|
|
2020
|
|
Vesting of stock options
|
|
$
|
2,064
|
|
|
$
|
1,730
|
|
|
Vesting of RSUs
|
|
435
|
|
|
706
|
|
|
Total share-based payments
|
|
$
|
2,499
|
|
|
$
|
2,436
|
|
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
(b)Stock options
Vesting conditions for grants of options are determined by the Compensation Committee of the Company’s Board of Directors. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three to five years with a maximum term of ten years. The typical vesting for stock option grants made under the Prior Option Plans is quarterly vesting over three to five years with a maximum term of seven years. The Prior Option Plans did not and the 2020 Omnibus Plan does not authorize grants of options with an exercise price below fair market value.
The following is a summary of the changes during the three months ended March 31, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price (C$) (i)
|
|
Number of options
|
|
Weighted average remaining contractual term (years)
|
|
Balance as of January 1, 2021
|
$
|
5.40
|
|
|
13,755,148
|
|
|
2.30
|
|
|
|
|
|
|
|
|
Exercise of options
|
2.13
|
|
|
(5,230,550)
|
|
|
|
|
Cancellation, forfeiture and expiry of options
|
14.71
|
|
|
(25,771)
|
|
|
|
|
Balance as of March 31, 2021
|
$
|
7.38
|
|
|
8,498,827
|
|
|
2.82
|
|
Exercisable as of March 31, 2021
|
$
|
5.75
|
|
|
4,896,820
|
|
|
1.46
|
(i)The weighted average exercise price reflects the conversion of foreign currency-denominated stock options translated into C$ using the average foreign exchange rate as of the date of issuance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price (C$)
|
|
Number of options
|
|
Weighted average remaining contractual term (years)
|
|
Balance as of January 1, 2020
|
$
|
4.84
|
|
|
14,149,502
|
|
|
2.56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancellation, forfeiture and expiry of options
|
17.17
|
|
|
(42,889)
|
|
|
|
|
Balance as of March 31, 2020
|
$
|
4.80
|
|
|
14,106,613
|
|
|
2.06
|
|
Exercisable as of March 31, 2020
|
$
|
3.11
|
|
|
9,783,544
|
|
|
1.66
|
The following table summarizes stock options outstanding for the 2020 Omnibus Plan, the 2018 Stock Option Plan, and the 2015 Stock Option Plan:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock options outstanding as of
|
|
|
March 31, 2021
|
|
December 31, 2020
|
|
2020 Omnibus Plan
|
2,000,000
|
|
|
2,000,000
|
|
|
2018 Stock Option Plan
|
1,591,944
|
|
1,627,715
|
|
|
2015 Stock Option Plan
|
4,906,883
|
|
|
10,127,433
|
|
|
Total stock options outstanding
|
8,498,827
|
|
13,755,148
|
|
(c)Restricted share units
The following is a summary of the changes in RSUs for the three months ended March 31, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of RSUs (i)
|
|
Weighted average grant date fair value (C$) (ii)
|
|
Balance as of January 1, 2021
|
948,357
|
|
|
$
|
7.66
|
|
|
Granted(i)
|
265,904
|
|
|
13.27
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of March 31, 2021
|
1,214,261
|
|
|
$
|
8.89
|
|
(i)RSUs issued in the period vest annually in equal installments over a three-year period following the grant date, subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria.
(ii)The weighted average exercise price reflects the conversion of foreign currency-denominated RSUs translated into C$ using the foreign exchange rate as of the date of issuance.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of RSUs
|
|
Weighted average grant date fair value (C$)
|
|
Balance as of January 1, 2020 and March 31, 2020
|
732,972
|
|
|
$
|
15.34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All RSUs outstanding as of March 31, 2021 and December 31, 2020 were granted under the 2020 Omnibus Plan.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
(d)Deferred share units
The following is a summary of the changes in DSUs during the three months ended March 31, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of DSUs
|
|
Financial liability
|
|
Balance as of January 1, 2021
|
83,293
|
|
|
$
|
577
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss (gain) on revaluation
|
—
|
|
|
211
|
|
|
Balance as of March 31, 2021
|
83,293
|
|
|
$
|
788
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of DSUs
|
|
Financial liability
|
|
Balance as of January 1, 2020
|
33,937
|
|
|
$
|
255
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss (gain) on revaluation
|
—
|
|
|
(50)
|
|
|
Balance as of March 31, 2020
|
33,937
|
|
|
$
|
205
|
|
All DSUs outstanding as of March 31, 2021 and December 31, 2020 were granted under the DSU Plan.
(e)Warrants
The following is a summary of the changes in warrants during the three months ended March 31, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price (C$)
|
|
Number of warrants
|
|
Balance as of January 1, 2021
|
$
|
0.25
|
|
|
7,987,349
|
|
|
Exercise of warrants
|
0.25
|
|
|
(7,977,349)
|
|
|
|
|
|
|
|
Balance as of March 31, 2021(i)
|
$
|
0.25
|
|
|
10,000
|
|
(i)The outstanding warrants were granted in the second quarter of 2016 and expire on May 27, 2021.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price (C$)
|
|
Number of warrants
|
|
Balance as of January 1, 2020 and March 31, 2020
|
$
|
0.26
|
|
|
18,066,662
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See Note 5. Derivative Liabilities for further description on the Altria Warrant.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
7. Earnings (Loss) per Share
Basic and diluted earnings (loss) per share from continuing operations are calculated using the following numerators and denominators:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended March 31,
|
|
|
|
|
2021
|
|
2020
|
|
|
|
|
|
Basic earnings per share computation
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common shareholders of Cronos Group
|
$
|
(161,312)
|
|
|
$
|
76,040
|
|
|
|
|
|
|
Weighted average number of common shares outstanding
|
363,012,740
|
|
|
348,817,472
|
|
|
|
|
|
|
Basic earnings per share(i)
|
$
|
(0.44)
|
|
|
$
|
0.22
|
|
|
|
|
|
|
Diluted earnings per share computation
|
|
|
|
|
|
|
|
|
Net income (loss) used in the computation of basic earnings per share
|
$
|
(161,312)
|
|
|
$
|
76,040
|
|
|
|
|
|
|
Adjustment for gain (loss) on revaluation of derivative liabilities
|
—
|
|
|
—
|
|
|
|
|
|
|
Net income (loss) used in the computation of diluted income per share
|
$
|
(161,312)
|
|
|
$
|
76,040
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares outstanding used in the computation of basic earnings per share
|
363,012,740
|
|
|
348,817,472
|
|
|
|
|
|
|
Dilutive effect of warrants
|
—
|
|
|
17,550,444
|
|
|
|
|
|
|
Dilutive effect of stock options
|
—
|
|
|
7,962,252
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares for computation of diluted income (loss) per share
|
363,012,740
|
|
|
374,330,168
|
|
|
|
|
|
|
Diluted earnings per share(i)
|
$
|
(0.44)
|
|
|
$
|
0.20
|
|
|
|
|
|
(i)Basic and dilutive earnings per share from discontinued operations were $0.00 and $0.00 for the three months ended March 31, 2021 and 2020, respectively.
(ii)In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive.
The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because conditions for contingently issuable shares were not satisfied at the end of the reporting periods.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31,
|
|
|
|
|
2021
|
|
2020
|
|
|
|
|
|
Ginkgo equity milestones
|
14,674,904
|
|
|
14,674,904
|
|
|
|
|
|
|
Pre-emptive Rights
|
11,285,001
|
|
|
12,006,740
|
|
|
|
|
|
|
Top-up Rights – fixed price
|
11,113,451
|
|
|
25,111,456
|
|
|
|
|
|
|
Top-up Rights – market price
|
2,623,082
|
|
|
1,941,349
|
|
|
|
|
|
|
Altria Warrant
|
82,590,353
|
|
|
77,514,993
|
|
|
|
|
|
|
Stock options
|
8,522,086
|
|
|
2,240,456
|
|
|
|
|
|
|
Warrants
|
5,563,176
|
|
|
—
|
|
|
|
|
|
|
Restricted share units
|
572,970
|
|
|
732,972
|
|
|
|
|
|
|
Total anti-dilutive securities
|
136,945,023
|
|
|
134,222,870
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
8. Segment Information
Segment reporting is prepared on the same basis that the Company’s chief operating decision makers (the “CODMs”) manage the business, make operating decisions and assess the Company’s performance. The Company determined that it has the following two reportable segments: United States and Rest of World. The United States operating segment consists of the manufacture and distribution of hemp-derived CBD infused products. The Rest of World operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. These two segments represent the geographic regions in which the Company operates and the different product offerings within each geographic region. The results of each segment are regularly reviewed by the CODMs to assess the performance of the segment and make decisions regarding the allocation of resources. The CODMs review adjusted earnings (loss) before interest, tax, depreciation and amortization (“Adjusted EBITDA”) as the measure of segment profit or loss to evaluate performance of and allocate resources for its reportable segments. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, non-cash items and items that do not reflect management’s assessment of on-going business performance.
Segment data was as follows for the three months ended March 31, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, 2021
|
|
|
United States
|
|
Rest of World
|
|
Corporate expenses
|
|
Total
|
|
Net revenue
|
|
|
|
|
|
|
|
|
Cannabis flower
|
$
|
—
|
|
|
$
|
9,434
|
|
|
$
|
—
|
|
|
$
|
9,434
|
|
|
Cannabis extracts
|
2,441
|
|
|
703
|
|
|
—
|
|
|
3,144
|
|
|
Other
|
—
|
|
|
33
|
|
|
—
|
|
|
33
|
|
|
Net revenue
|
$
|
2,441
|
|
|
$
|
10,170
|
|
|
$
|
—
|
|
|
$
|
12,611
|
|
|
|
|
|
|
|
|
|
|
|
Share of loss from investments in equity accounted investees
|
$
|
—
|
|
|
$
|
1,643
|
|
|
$
|
—
|
|
|
$
|
1,643
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
3
|
|
|
2,332
|
|
|
—
|
|
|
2,335
|
|
|
Interest expense
|
—
|
|
|
(6)
|
|
|
—
|
|
|
(6)
|
|
|
Interest income, net
|
$
|
3
|
|
|
$
|
2,326
|
|
|
$
|
—
|
|
|
$
|
2,329
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
$
|
71
|
|
|
$
|
664
|
|
|
$
|
—
|
|
|
$
|
735
|
|
|
Impairment loss on property, plant and equipment and right-of-use assets
|
1,741
|
|
|
—
|
|
|
—
|
|
|
1,741
|
|
|
Loss from discontinued operations
|
—
|
|
|
21
|
|
|
—
|
|
|
21
|
|
|
Adjusted EBITDA
|
(9,510)
|
|
|
(22,184)
|
|
|
(5,381)
|
|
|
(37,075)
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
252,449
|
|
|
394,442
|
|
|
1,234,391
|
|
|
1,881,282
|
|
|
Investments in equity accounted investees
|
—
|
|
|
19,221
|
|
|
—
|
|
|
19,221
|
|
|
Goodwill
|
178,416
|
|
|
1,115
|
|
|
—
|
|
|
179,531
|
|
|
Purchase of property, plant and equipment, net
|
80
|
|
|
6,600
|
|
|
—
|
|
|
6,680
|
|
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, 2020
|
|
|
United States
|
|
Rest of World
|
|
Corporate expenses
|
|
Total
|
|
Net revenue
|
|
|
|
|
|
|
|
|
Cannabis flower
|
$
|
—
|
|
|
$
|
2,741
|
|
|
$
|
—
|
|
|
$
|
2,741
|
|
|
Cannabis extracts
|
2,176
|
|
|
3,400
|
|
|
—
|
|
|
5,576
|
|
|
Other
|
—
|
|
|
115
|
|
|
—
|
|
|
115
|
|
|
Net revenue
|
$
|
2,176
|
|
|
$
|
6,256
|
|
|
$
|
—
|
|
|
$
|
8,432
|
|
|
|
|
|
|
|
|
|
|
|
Share of loss from investments in equity accounted investees
|
$
|
—
|
|
|
$
|
1,172
|
|
|
$
|
—
|
|
|
$
|
1,172
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
7
|
|
|
7,751
|
|
|
—
|
|
|
7,758
|
|
|
Interest expense
|
—
|
|
|
(7)
|
|
|
—
|
|
|
(7)
|
|
|
Interest income, net
|
$
|
7
|
|
|
$
|
7,744
|
|
|
$
|
—
|
|
|
$
|
7,751
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
33
|
|
|
654
|
|
|
—
|
|
|
687
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA
|
$
|
(5,782)
|
|
|
$
|
(29,010)
|
|
|
$
|
(2,263)
|
|
|
$
|
(37,055)
|
|
Adjusted EBITDA is reconciled to net income (loss) as follows for the three months ended March 31, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
Three months ended March 31, 2021
|
|
|
US
|
|
ROW
|
|
Corporate
Expenses
|
|
Total
|
|
Net income (loss)
|
$
|
(12,092)
|
|
|
$
|
(142,147)
|
|
|
$
|
(7,386)
|
|
|
$
|
(161,625)
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Interest income, net
|
(3)
|
|
|
(2,326)
|
|
|
—
|
|
|
(2,329)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impairment loss on property, plant and equipment and right-of-use assets
|
1,741
|
|
|
—
|
|
|
—
|
|
|
1,741
|
|
Loss on revaluation of derivative liabilities
|
—
|
|
|
116,874
|
|
|
—
|
|
|
116,874
|
|
|
|
|
|
|
|
|
|
|
Other loss
|
—
|
|
|
1,859
|
|
|
—
|
|
|
1,859
|
|
Loss from discontinued operations
|
—
|
|
|
21
|
|
|
—
|
|
|
21
|
|
Share-based payments
|
745
|
|
|
1,754
|
|
|
—
|
|
|
2,499
|
|
Review costs related to restatement of 2019 interim financial statements
|
—
|
|
|
—
|
|
|
2,005
|
|
|
2,005
|
|
Adjusted EBIT
|
(9,609)
|
|
|
(23,965)
|
|
|
(5,381)
|
|
|
(38,955)
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
99
|
|
|
1,781
|
|
|
—
|
|
|
1,880
|
|
Adjusted EBITDA
|
$
|
(9,510)
|
|
|
$
|
(22,184)
|
|
|
$
|
(5,381)
|
|
|
$
|
(37,075)
|
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
Three months ended March 31, 2020
|
|
|
US
|
|
ROW
|
|
Corporate
Expenses
|
|
Total
|
|
Net income (loss)
|
$
|
(6,516)
|
|
|
$
|
88,867
|
|
|
$
|
(6,670)
|
|
|
$
|
75,681
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Interest income, net
|
(7)
|
|
|
(7,744)
|
|
|
—
|
|
|
(7,751)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on revaluation of derivative liabilities
|
—
|
|
|
(113,368)
|
|
|
—
|
|
|
(113,368)
|
|
Other loss
|
—
|
|
|
378
|
|
|
—
|
|
|
378
|
|
|
|
|
|
|
|
|
|
|
Share-based payments
|
706
|
|
|
1,730
|
|
|
—
|
|
|
2,436
|
|
Review costs related to restatement of 2019 interim financial statements
|
—
|
|
|
—
|
|
|
4,407
|
|
|
4,407
|
|
Adjusted EBIT
|
(5,817)
|
|
|
(30,137)
|
|
|
(2,263)
|
|
|
(38,217)
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
35
|
|
|
1,127
|
|
|
—
|
|
|
1,162
|
|
Adjusted EBITDA
|
$
|
(5,782)
|
|
|
$
|
(29,010)
|
|
|
$
|
(2,263)
|
|
|
$
|
(37,055)
|
Sources of net revenue for the three months ended March 31, 2021 and 2020 were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31,
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
|
|
|
|
Cannabis flower
|
|
|
|
|
$
|
9,434
|
|
|
$
|
2,741
|
|
|
|
|
|
|
Cannabis extracts
|
|
|
|
|
3,144
|
|
|
5,576
|
|
|
|
|
|
|
Other
|
|
|
|
|
33
|
|
|
115
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
$
|
12,611
|
|
|
$
|
8,432
|
|
|
|
|
|
Net revenue attributed to a geographic region based on the location of the customer were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31,
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
|
|
|
|
Canada
|
|
|
|
|
$
|
7,582
|
|
|
$
|
6,091
|
|
|
|
|
|
|
Israel
|
|
|
|
|
2,518
|
|
|
—
|
|
|
|
|
|
|
United States
|
|
|
|
|
2,441
|
|
|
2,176
|
|
|
|
|
|
|
Other countries
|
|
|
|
|
70
|
|
|
165
|
|
|
|
|
|
|
Net revenue
|
|
|
|
|
$
|
12,611
|
|
|
$
|
8,432
|
|
|
|
|
|
Property, plant and equipment assets were physically located in the following geographic regions:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2021
|
|
As of December 31, 2020
|
|
Canada
|
$
|
167,363
|
|
|
$
|
162,163
|
|
|
Israel
|
23,480
|
|
|
23,143
|
|
|
United States
|
1,280
|
|
|
2,293
|
|
|
|
|
|
|
|
Total
|
$
|
192,123
|
|
|
$
|
187,599
|
|
The Company sells products through a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company’s revenues and greater than 10% of accounts receivable.
United States
During the three months ended March 31, 2021 and 2020, the U.S. segment had no major customers.
As of March 31, 2021 and December 31, 2020, the Company had $36 and $65, respectively, in expected credit losses that have been recognized on receivables from contracts with customers.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
Rest of World
During the three months ended March 31, 2021, the Rest of World segment earned a total net revenue before excise taxes of $8,963 from four major customers, Société Québécoise du Cannabis, Novolog Group, Alberta Gaming, Liquor and Cannabis Commission and Ontario Cannabis Retail Corporation, accounting for 18%, 17%, 13% and 13%, respectively, of the Company’s total net revenue before excise taxes.
During the three months ended March 31, 2020, the Rest of World segment earned a total net revenue before excise taxes of $4,121 from 3 major customers, together accounting for 49% of the Company’s total net revenues before excise taxes.
As of March 31, 2021 and December 31, 2020, the Company had $30 and $9, respectively, in expected credit losses that have been recognized on receivables from contracts with customers.
The loss from discontinued operations from the Rest of World segment for the three months ended March 31, 2021 and 2020 was $21 and $nil, respectively.
9. Commitments and Contingencies
(a)Commitments
There has been no material change in the information regarding commitments as disclosed in the Company’s Annual Financial Statements.
(b)Contingencies
The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter.
(i)Class action complaints relating to restatement
On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its former Chief Executive Officer (now Executive Chairman) and Chief Financial Officer. The court has consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company’s prior public statements about revenues and internal controls were incorrect based on the Company’s disclosures relating to the Audit Committee of the Board of Directors’ review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. Defendants moved to dismiss on February 8, 2021.
On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim names the Company, its former Chief Executive Officer (now Executive Chairman), Chief Financial Officer, former Chief Financial Officer and Chief Commercial Officer, and current and former members of the Board of Directors as defendants and alleges breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleges that certain of the Company’s prior public statements about revenues and internal controls were misrepresentations based on the Company’s March 2, 2020 disclosure that the Audit Committee of the Board of Directors was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company’s subsequent restatement. The Amended Statement of Claim does not quantify a damage request.
(ii)Regulatory reviews relating to restatement
The Company has been responding to requests for information from various regulatory authorities relating to its previously disclosed restatement of its financial statements for the first three quarters of 2019. The Company is responding to all such requests for information and cooperating with all regulatory authorities. The Company cannot predict the outcome of any such regulatory review or investigation and it is possible that additional investigations or one or more formal proceedings may be commenced against the Company and its current and former officers and directors in connection with these regulatory reviews and investigations.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
(iii)Litigation relating to marketing, distribution and sale of products
On June 16, 2020, an alleged consumer filed a Statement of Claim on behalf of a class in the Court of Queen’s Bench of Alberta in Alberta, Canada, against the Company and other Canadian cannabis manufacturers and/or distributors. On December 4, 2020, a Third Amended Statement of Claim was filed, which added a second alleged consumer. The Third Amended Statement of Claim alleges claims related to the defendants’ advertised content of cannabinoids in cannabis products for medicinal use on or after June 16, 2010 and cannabis products for adult use on or after October 17, 2018. The Third Amended Statement of Claim seeks a total of C$500 million for breach of contract, compensatory damages, and unjust enrichment or such other amount as may be proven in trial and C$5 million in punitive damages against each defendant, including the Company. The Third Amended Statement of Claim also seeks interest and costs associated with the action. The Company has not responded to the Third Amended Statement of Claim.
A number of claims, including purported class actions, have been brought in the U.S. against companies engaged in the U.S. hemp business alleging, among other things, violations of state consumer protection, health and advertising laws. On April 8, 2020, a putative class action complaint was filed in the U.S. District Court for the Central District of California against Redwood Holding Group, LLC (“Redwood”), alleging violations of California’s Unfair Competition Law, False Advertising Law, Consumers Legal Remedies Act, and breaches of the California Commercial Code for breach of express warranties and implied warranty of merchantability with respect to Redwood’s marketing and sale of U.S. hemp products. The complaint did not quantify a damage request. On April 10, 2020, the class action complaint was dismissed for certain pleading deficiencies and the plaintiff was granted leave until April 24, 2020 to amend the complaint to establish federal subject matter jurisdiction. On April 28, 2020, the action was dismissed without prejudice for failure to prosecute and for failure to comply with a court order. As of the date of this Quarterly Report, the plaintiff has not refiled the complaint. The Company expects litigation and regulatory proceedings relating to the marketing, distribution and sale of its products to increase.
10. Financial Instruments
(a)Fair Value Measurement
The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by:
•Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.
•Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves.
•Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability.
The following tables present information about the Company’s assets that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2021
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
|
Cash and cash equivalents
|
$
|
1,024,450
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,024,450
|
|
|
Short-term investments
|
214,925
|
|
|
—
|
|
|
—
|
|
|
214,925
|
|
|
Derivative liabilities
|
—
|
|
|
—
|
|
|
272,300
|
|
|
272,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2020
|
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
|
|
Cash and cash equivalents
|
$
|
1,078,023
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,078,023
|
|
|
|
Short-term investments
|
211,766
|
|
|
—
|
|
|
—
|
|
|
211,766
|
|
|
|
Derivative liabilities
|
—
|
|
|
—
|
|
|
163,410
|
|
|
163,410
|
|
|
There were no transfers between categories during the periods presented.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
(b)Financial Risks
The Company’s activities expose it to a variety of financial risks, including credit risk, market risk, interest rate risk, liquidity risk, and foreign currency rate risk.
(i)Credit risk
Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments, loan receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to $1,348,325 and $1,403,491 as of March 31, 2021 and December 31, 2020, respectively.
(a)Cash and cash equivalents, short-term investments, and other receivables
The Company held cash and cash equivalents of $1,024,450 and $1,078,023 as of March 31, 2021 and December 31, 2020, respectively. The short-term investments and related interest receivable of $214,925 and $211,766, as of March 31, 2021 and December 31, 2020 respectively, represents short-term investments with a maturity of less than a year and accrued interest as of period end. The cash and cash equivalents and short-term investments, including guaranteed investment certificates and bankers’ acceptances, are held with central banks and financial institutions that are highly rated. In addition to interest receivable, other receivables include sales taxes receivable from the government. As such, the Company has assessed an insignificant loss allowance on these financial instruments.
(b)Accounts receivable
An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, among others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of March 31, 2021 and December 31, 2020, the Company recorded a current expected credit loss allowance of $66 and $74, respectively. As of March 31, 2021, the Company has assessed that there is a concentration of credit risk, as 63% of the Company’s accounts receivable were due from three customers with an established credit history with the Company. As of December 31, 2020, 78% of the Company’s accounts receivable were due from four customers with an established credit history with the Company.
(ii)Market risk
Market risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in market prices. The value of financial instruments can be affected by changes in interest rates, market and economic conditions, and equity and commodity prices. The Company is exposed to market risk in divesting its investments, such that unfavorable market conditions could result in dispositions of investments at less than their carrying values. Further, the revaluation of securities classified as fair value through net income could result in significant write-downs of the Company’s investments, which would have an adverse impact on the Company’s financial position, unless these would flow through other comprehensive income.
The Company manages market risk by having a portfolio of securities from multiple issuers so that the Company is not materially exposed to any one issuer.
(iii)Interest rate risk
Interest rate risk is the risk that the value or yield of fixed-income investments may decline if interest rates change. Fluctuations in interest rates may impact the level of income and expense recorded on the cash equivalents and short-term investments, and the market value of all interest-earning assets, other than those which possess a short-term to maturity. A 10% change in the interest rate in effect on March 31, 2021 and December 31, 2020 would not have a material effect on (i) fair value of the cash equivalents and short-term investments as the majority of the portfolio has a maturity date of three months or less or (ii) interest income. Management continues to monitor external interest rates and revise the Company’s investment strategy as a result.
During the three months ended March 31, 2021 and 2020, the Company had net interest income of $2,329 and $7,751, respectively.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
(iv)Liquidity risk
Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due and arises principally from the Company’s accounts payable and other liabilities. The Company’s policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company’s management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. The Company’s funding was primarily provided in the form of capital raised through the issuance of common shares and warrants. As of March 31, 2021, the Company had assessed a concentration risk of vendors as 26% of accounts payables were due to two vendors. As of December 31, 2020, the Company had assessed a concentration risk of vendors as 64% due to four vendors.
(v)Foreign currency risk
Currency rate risk is the risk that the fair value of, or future cash flows from, the Company’s financial instruments will significantly fluctuate due to changes in foreign exchange rates. The Company is exposed to this risk on investments in equity investees denominated in dollars, A$ and C$, and other assets and liabilities denominated in A$ and C$. The Company is further exposed to this risk through subsidiaries operating in Israel and the U.S. as the Company’s functional currency is in Canadian dollars. The Company does not currently use foreign exchange contracts to hedge its exposure to currency rate risk. As such, the Company’s financial position and financial results may be adversely affected by the unfavorable fluctuations in currency exchange rates.
During the three months ended March 31, 2021 and 2020, the Company had foreign currency gain (loss) on translation of $16,284 and $(113,692), respectively. A 10% change in the exchange rates for the U.S. dollar would affect the carrying value of net assets by approximately $156,828 and $170,817 as of March 31, 2021 and December 31, 2020, respectively.
11. Held-For-Sale Assets and Discontinued Operations
During the year ended December 31, 2020, the Company advanced its plans for the sale and disposal of substantially all of the assets of Original B.C. Ltd. (“OGBC”) and as a result, OGBC’s results of operations were reclassified as discontinued operations in the accompanying condensed consolidated financial statements. As of March 31, 2021, the assets and liabilities of OGBC continue to meet the definition of discontinued operations and are included as “held-for-sale” assets on the condensed consolidated balance sheet as of March 31, 2021 and December 31, 2020, and loss from discontinued operations on the condensed consolidated statements of net income and comprehensive income for the three months ended March 31, 2021 and 2020.
During the three months ended March 31, 2021, the Company advanced its plans for the sale of land and office premises (approximately 80,173 combined square feet) located in Winnipeg, Manitoba, Canada and accounted for in the Rest of World segment. The sale is expected to be made within the next twelve months and the criteria for the land and office premises to be classified as “held-for-sale” were met during the three months ended March 31, 2021. As a result, the assets are classified as “held-for-sale” assets as of March 31, 2021.
The following table summarizes the financial information for discontinued operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
|
|
|
|
Loss from discontinued operations, net of income taxes
|
|
|
|
|
|
|
|
|
|
$
|
(21)
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2021
|
|
December 31, 2020
|
|
OGBC assets classified as held-for-sale
|
|
|
|
|
|
|
|
|
|
|
$
|
1,195
|
|
|
$
|
1,176
|
|
|
Other property, plant and equipment classified as held-for-sale
|
|
|
|
|
|
|
|
|
|
|
774
|
|
|
—
|
|
|
Held-for-sale assets
|
|
|
|
|
|
|
|
|
|
|
$
|
1,969
|
|
|
$
|
1,176
|
|
12. Related Party Transactions and Balances
There have been no material related party transactions during the three months ended March 31, 2021 and 2020. As of March 31, 2021 and December 31, 2020 there were no material related party receivables or payables.
|
|
|
|
|
|
|
|
Cronos Group Inc.
|
|
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
|
|
|
|
|
(In thousands of $, except gram and share amounts)
|
|
13. Impairment Loss on Property, Plant and Equipment and Right-of-Use Assets
During the three months ended March 31, 2021, the Company recognized an impairment charge of $1,019 related to leasehold improvements located within leased premises, encompassing approximately 6,000 square feet, in Los Angeles, California, which the Company determined it no longer had plans to use. The significant change in the extent and manner in which the leasehold improvements are being used and the expectation that, more likely than not, the leasehold improvements will be disposed of before the end of their useful life triggered an impairment. The right-of-use lease asset associated with the leasehold improvements was also written down as a result of our decision to no longer use the leased premises. The Company recognized an impairment charge on the de-recognition of the right-of-use asset of $702 during the three months ended March 31, 2021. Both the impairment charges are recognized in the statement of net income (loss) as an impairment loss on property, plant and equipment and right-of-use assets.
14. Subsequent Events
On April 1, 2021, the Company and an affiliate of Agroidea (“AGI”), the other joint venture partner of Natuera, agreed to convert all advances made to Natuera under the Series A Loan, plus accrued interest, into equity. Total aggregate gross advances to Natuera under the Series A Loan were $15,500, of which the Company advanced 50% and AGI advanced the remaining 50%, for an amount of $7,750 each. As a result, the Company transferred the carrying value of the loan of $2,013 plus accrued interest, which approximates fair value, to investments in equity accounted investees in respect of Natuera.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis should be read together with other information, including Cronos Group’s condensed consolidated financial statements and the related notes to those statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 (this “Quarterly Report”), consolidated financial statements appearing in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 (the “Annual Report”) and Part I, Item 1A, Risk Factors, of the Annual Report.
Forward-Looking Statements
This Quarterly Report, the documents incorporated into this Quarterly Report by reference, other reports we file with, or furnish to, the U.S. Securities and Exchange Commission (“SEC”) and other regulatory agencies, and statements by our directors, officers, other employees and other persons authorized to speak on our behalf contain information that may constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (collectively, “Forward-Looking Statements”), which are based upon our current internal expectations, estimates, projections, assumptions and beliefs. All information that is not clearly historical in nature may constitute Forward-Looking Statements. In some cases, Forward-Looking Statements can be identified by the use of forward-looking terminology, such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, expressions and phrases, including negative and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussion of strategy. Forward-Looking Statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of historical fact.
Forward-Looking Statements include, but are not limited to, statements with respect to:
•the uncertainties associated with the COVID-19 pandemic, including our ability, and the abilities of our joint ventures and our suppliers and distributors, to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic, the ability to continue our production, distribution and sale of our products, and demand for and the use of our products by consumers;
•laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of United States (“U.S.”) state and federal law to U.S. hemp (including CBD) products and the scope of any regulations by the U.S. Food and Drug Administration (the “FDA”), the U.S. Drug Enforcement Administration (the “DEA”), the U.S. Federal Trade Commission (the “FTC”), the U.S. Patent and Trademark Office (the “PTO”) and any state equivalent regulatory agencies over U.S. hemp (including CBD) products;
•the laws and regulations and any amendments thereto relating to the U.S. hemp industry in the U.S., including the promulgation of regulations for the U.S. hemp industry by the U.S. Department of Agriculture (the “USDA”) and relevant state regulatory authorities;
•the grant, renewal and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof;
•our international activities and joint venture interests, including required regulatory approvals and licensing, anticipated costs and timing, and expected impact;
•our ability to successfully create and launch brands and further create, launch and scale U.S. hemp-derived consumer products and cannabis products;
•the benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, including CBD and other cannabinoids;
•expectations regarding the implementation and effectiveness of key personnel changes;
•the anticipated benefits and impact of the Altria Investment (as defined herein);
•the potential exercise of the Altria Warrant (as defined herein), pre-emptive rights and/or top-up rights in connection with the Altria Investment, including proceeds to us that may result therefrom;
•expectations regarding the use of proceeds of equity financings, including the proceeds from the Altria Investment;
•the legalization of the use of cannabis for medical or adult-use in jurisdictions outside of Canada, the related timing and impact thereof and our intentions to participate in such markets, if and when such use is legalized;
•expectations regarding the potential success of, and the costs and benefits associated with, our joint ventures, strategic alliances and equity investments, including the strategic partnership (the “Ginkgo Strategic Partnership”) with Ginkgo Bioworks, Inc. (“Ginkgo”);
•our ability to execute on our strategy and the anticipated benefits of such strategy;
•expectations of the amount or frequency of impairment losses, including as a result of the write-down of intangible assets, including goodwill;
•the ongoing impact of the legalization of additional cannabis product types and forms for adult-use in Canada, including federal, provincial, territorial and municipal regulations pertaining thereto, the related timing and impact thereof and our intentions to participate in such markets;
•the future performance of our business and operations;
•our competitive advantages and business strategies;
•the competitive conditions of the industry;
•the expected growth in the number of customers using our products;
•our ability or plans to identify, develop, commercialize or expand our technology and research and development (“R&D”) initiatives in cannabinoids, or the success thereof;
•expectations regarding acquisitions and dispositions and the anticipated benefits therefrom, including the proposed sale of our Original B.C. Ltd. (“OGBC”) production facility;
•expectations regarding revenues, expenses and anticipated cash needs;
•expectations regarding cash flow, liquidity and sources of funding;
•expectations regarding capital expenditures;
•the expansion of our production and manufacturing, the costs and timing associated therewith and the receipt of applicable production and sale licenses;
•the expected growth in our growing, production and supply chain capacities;
•expectations regarding the resolution of litigation and other legal and regulatory proceedings, reviews and investigations;
•expectations with respect to future production costs;
•expectations with respect to future sales and distribution channels and networks;
•the expected methods to be used to distribute and sell our products;
•the anticipated future gross margins of our operations;
•accounting standards and estimates;
•our ability to timely and effectively remediate any material weaknesses in our internal control over financial reporting; and
•expectations regarding the costs and benefits associated with our contracts and agreements with third parties, including under our third-party supply and manufacturing agreements.
Certain of the Forward-Looking Statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.
The Forward-Looking Statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) our ability, and the abilities of our joint ventures and our suppliers and distributors, to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic and the ability to continue our production, distribution and sale of our products and customer demand for and use of our products; (ii) management’s perceptions of historical trends, current conditions and expected future developments; (iii) our ability to generate cash flow from operations; (iv) general economic, financial market, regulatory and political conditions in which we operate; (v) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (vi) consumer interest in our products; (vii) competition; (viii) anticipated and unanticipated costs; (ix) government regulation of our activities and products including, but not limited to, the areas of taxation and environmental protection; (x) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (xi) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xii) our ability to conduct operations in a safe, efficient and effective manner; (xiii) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; (xiv) our ability to complete planned dispositions, including the sale of OGBC, and, if completed, obtain our anticipated sales price; and (xv) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.
By their nature, Forward-Looking Statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the Forward-Looking Statements in this Quarterly Report and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, the risk that the COVID-19 pandemic may disrupt our operations and those of our suppliers and distribution channels and negatively impact the demand for and use of our products; the risk that cost savings and any other synergies from the Altria Investment may not be fully realized or may take longer to realize than expected; the risk that we will not complete planned dispositions, including the sale of OGBC, or, if completed, obtain our anticipated sales price; the implementation and effectiveness of key personnel changes; future levels of revenues; consumer demand for cannabis and U.S. hemp products; our ability to manage disruptions in credit markets or changes to our credit ratings; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; the success or timing of completion of ongoing or anticipated capital or maintenance projects; business strategies, growth opportunities and expected investment; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the expected timeframe or at all); the potential effects of judicial, regulatory or other proceedings, or threatened litigation or proceedings, on our business, financial condition, results of operations and cash flows; volatility in and/or degradation of general economic, market, industry or business conditions; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and U.S. hemp products in vaping devices; the anticipated effects of actions of third parties such as competitors, activist investors or federal (including U.S. federal), state, provincial, territorial or local regulatory authorities or self-regulatory organizations; changes in regulatory requirements in relation to our business and products; and the factors discussed under Part I, Item 1A, “Risk Factors” of the Annual Report. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on Forward-Looking Statements.
Forward-Looking Statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present information about management’s current expectations and plans relating to the future, and the reader is cautioned that the Forward-Looking Statements may not be appropriate for any other purpose. While we believe that the assumptions and expectations reflected in the Forward-Looking Statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-Looking Statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such Forward-Looking Statements. The Forward-Looking Statements contained in this Quarterly Report and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.
Foreign currency exchange rates
All currency amounts in this Quarterly Report are stated in U.S. dollars, which is our reporting currency, unless otherwise noted. All references to “dollars” or “$” are to U.S. dollars. The assets and liabilities of the Company’s foreign operations are translated into dollars at the exchange rate in effect as of March 31, 2021, December 31, 2020 and March 31, 2020. Transactions affecting the shareholders’ equity (deficit) are translated at historical foreign exchange rates. The consolidated statements of net income (loss) and comprehensive income (loss) and consolidated statements of cash flows of the Company’s foreign operations are translated into dollars by applying the average foreign exchange rate in effect for the reporting period using Bloomberg.
The exchange rates used to translate from Canadian dollars (“C$”) to dollars is shown below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Exchange rates are shown as C$ per $)
|
As of
|
|
|
March 31, 2021
|
|
March 31, 2020
|
|
December 31, 2020
|
|
Average rate
|
1.2665
|
|
1.3437
|
|
1.3036
|
|
Spot rate
|
1.2563
|
|
1.4062
|
|
1.2751
|
|
|
|
|
|
|
|
|
Year-to-date average rate
|
1.2665
|
|
1.3437
|
|
1.3411
|
Business Overview
Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development and is building an iconic brand portfolio. Cronos Group’s brand portfolio includes PEACE NATURALS™, a global wellness platform; two adult-use brands, COVE™ and Spinach™; and three U.S. hemp-derived consumer products brands, Lord Jones™, Happy Dance™ and PEACE+™.
Strategy
Cronos Group seeks to create value for shareholders by focusing on four core strategic priorities:
•growing a portfolio of iconic brands that responsibly elevate the consumer experience;
•developing a diversified global sales and distribution network;
•establishing an efficient global supply chain; and
•creating and monetizing disruptive intellectual property.
Business segments
Cronos Group reports through two segments: “United States” and “Rest of World.” These two segments represent the geographic regions in which the Company operates and the different product offerings within each geographic region.
The United States segment manufactures, markets and distributes U.S. hemp-derived supplements and cosmetic products through e-commerce, retail and hospitality partner channels in the United States under the brands Lord Jones™ and Happy Dance™.
The Rest of World segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. In Canada, Cronos Group operates a wholly owned license holder under the Cannabis Act (Canada), Peace Naturals Project Inc. (“Peace Naturals”), which has production facilities near Stayner, Ontario (the “Peace Naturals Campus”). In Israel, the Company operates under the IMC-GAP, IMC-GMP and IMC-GDP certifications required for the cultivation, production and marketing of dried flower, pre-rolls and cannabis oils in the Israeli medical market. Cronos Group has established strategic joint ventures in Canada, Israel and Colombia. Cronos Group additionally holds approximately 31% of the issued capital of Cronos Australia Limited, which is listed on the Australian Securities Exchange under the trading symbol “CAU.” Cronos Group currently exports cannabis products to countries that permit the import of such products, such as Australia, Germany and Israel.
Recent Developments
COVID-19 update
The COVID-19 pandemic continues to impact the global economy and, specifically, the U.S., Canada, Israel, and the other countries in which the Company or its affiliates operate (including Australia and Colombia). Cronos Group continues to closely monitor and respond, where possible, to the ongoing COVID-19 pandemic. As the global situation continues to change rapidly, ensuring the health and safety of our employees remains one of our top priorities.
In the U.S., various states have begun rolling back their COVID-19 related restrictions as the continued rollout of vaccines has accelerated. This has resulted in the re-opening of, and increased occupancy capacities in, retail outlets, including those that sell the Company’s products. There are, however, indications that the pace of vaccinations may be slowing. Any reinstatement of restrictions on the operations of retail outlets could negatively impact the Company’s short-term results of operations in the U.S.
In Canada, in response to a recent surge in infection rates, individual provinces are taking increasingly stronger measures to slow infection rates, including stay-at-home orders and temporary closures of retail outlets, including cannabis stores. Most provinces, however, allow curbside pick-up or delivery, replacing in-person visits to cannabis stores. The measures taken to slow infection rates are expected to have a negative impact on the Company’s short-term revenue growth in Canada. The roll-out of vaccines in individual provinces has continued, but the pace of the roll-out has varied between the provinces, and the rate of vaccination in Canada is lower than in the U.S. and Israel.
In Israel, COVID-19 restrictions have been gradually eased as vaccination rates have increased to cover over 50% of its population and daily infection rates remain low. Occupancy limitations are still in place in retail outlets, including those that sell the Company’s products. The Company does not expect these measures to have a material impact on the Company’s short-term revenue growth in Israel.
In both the U.S. and ROW segments, there were no material increases in the current expected credit loss in connection with COVID-19. The Company continues to closely monitor the effects of COVID-19 on its operating results.
Collectively, the effects of the COVID-19 pandemic have adversely affected the Company’s results of operations and, if the effects continue unabated, could continue to do so as long as measures to combat the COVID-19 pandemic remain in effect. At this time,
neither the duration nor scope of the disruption can be predicted; therefore, the ultimate impact to the Company’s business cannot be reasonably estimated but such impact could materially adversely affect the Company’s business and financial results.
Despite the impacts of the COVID-19 pandemic, the Company believes that its significant cash on hand and short-term investments will be adequate to meet liquidity and capital requirements for at least the next twelve months. The impact of reduced interest rates has inhibited the Company’s ability to generate interest income, but this has not had, and is not expected to have, a material impact on the liquidity or capital resources of the Company.
Brand and Product Portfolio
In April 2021, Cronos Group announced that its Lord Jones™ brand launched a robust brand campaign entitled, “A Higher Order”. The campaign features new creative assets along with a mix of market activations including out-of-home advertising and television spots in select U.S. test markets. This new Lord Jones™ campaign reaffirms the Company’s commitment to robust, breakthrough marketing and brand building that aims to bring high-quality U.S. hemp-derived CBD products to adult consumers.
In the coming weeks, Cronos Group’s mainstream adult-use brand, Spinach™, intends to launch edibles, a new product category for Cronos Group, in the Canadian adult-use market. This product has been developed by the Company’s world class innovation and R&D teams in partnership with various teams throughout the organization such as consumer insights, marketing, and sales. Cronos Group approaches product launches with an aim to be the best, not necessarily the first. The adult-use edibles are differentiated from what is currently on the market and seeks to provide an elevated experience for the consumer. The Company’s new edibles capabilities will serve as a platform for future innovation that is expected to provide Cronos Group with a robust competitive advantage.
In April 2021, the Lord Jones™ brand launched a new product, the Lord Jones™ CBD Bump & Smooth Body Serum, which is designed to deliver non-abrasive chemical exfoliation that reduces bumpiness to reveal smoother, brighter looking skin. The product is available on the Lord Jones™ website and is expected to be on Sephora's website and in their retail outlets in the coming weeks.
In the first quarter of 2021, Cronos Israel successfully launched PEACE NATURALS™ branded pre-rolls into the Israeli medical cannabis market. This launch follows the successful launch of dried flower and oils to the Israeli medical cannabis market in 2020. Cronos Israel continues to execute in Israel's rapidly growing market.
Global Supply Chain
In the first quarter of 2021, Natuera, the Company’s joint venture in Latin America, successfully exported THC cannabis derivatives from Colombia to the U.S. for R&D purposes. The import was conducted under a DEA permit for R&D purposes. Additionally, Natuera's wholly owned subsidiary has been granted quotas by Colombia's Ministry of Justice and Law and Ministry of Health and Social Protection for the cultivation and manufacture of psychoactive cannabis into THC products for commercial export.
In the first quarter of 2021, Cronos GrowCo, the Company’s joint venture in Canada, continued to become operational in phases, completing its first harvest in the first quarter of 2021. In addition to having a cultivation license for the operations contemplated by the first phase of the project, Cronos GrowCo has received a processing license, allowing it to sell into the Canadian cannabis wholesale market.
Intellectual Property Initiatives
In April 2021, Cronos Fermentation, Cronos Group’s GMP-standard fermentation and manufacturing facility in Winnipeg, Manitoba, received its processing license. This is a significant milestone not just for Cronos Group, but for the evolution of the industry and advancements in science that will be applied in an effort to elevate the consumer experience.
Enterprise Initiatives
In April 2021, Cronos Group announced the launch of its U.S. Cronos Employees Political Action Committee (the “Employees PAC”). The Employees PAC was established to support and educate legislators who are open to responsibly advancing legislation and regulation for U.S. hemp-derived CBD products in the U.S. market and supporting a regulated, safe and legal federal cannabis industry in the U.S.
Subsequent to the end of the first quarter in April 2021, the Company expanded the implementation of its new enterprise resource planning (“ERP”) system to the U.S. segment. This follows the implementation of a new ERP system across the Canadian business in the third quarter of 2020. The new ERP system will be a meaningful component of the Company's internal control over financial reporting and is expected to enable us to realize efficiencies throughout our supply chain and operations.
Consolidated Results of Operations: Q1 2021 compared with Q1 2020
Summary of financial results – consolidated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Net revenue
|
|
|
|
|
|
|
|
|
$
|
12,611
|
|
|
$
|
8,432
|
|
|
$
|
4,179
|
|
|
50
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
|
|
|
|
|
|
(2,963)
|
|
|
(6,476)
|
|
|
3,513
|
|
|
(54)
|
%
|
|
Gross margin
|
|
|
|
|
|
|
|
|
(23)
|
%
|
|
(77)
|
%
|
|
N/A
|
|
54
|
pp
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA (i)
|
|
|
|
|
|
|
|
|
$
|
(37,075)
|
|
|
$
|
(37,055)
|
|
|
$
|
(20)
|
|
|
—
|
%
|
(i) See “Non-GAAP measures” for information related to Non-GAAP measures.
Net revenue – consolidated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Net revenue, before excise taxes (i)
|
|
|
|
|
|
|
|
|
$
|
14,654
|
|
|
$
|
9,344
|
|
|
$
|
5,310
|
|
|
57
|
%
|
|
Excise taxes
|
|
|
|
|
|
|
|
|
(2,043)
|
|
|
(912)
|
|
|
(1,131)
|
|
|
124
|
%
|
|
Net revenue
|
|
|
|
|
|
|
|
|
$
|
12,611
|
|
|
$
|
8,432
|
|
|
$
|
4,179
|
|
|
50
|
%
|
(i) Net revenue, before excise taxes, is calculated net of sales returns and discounts.
For the three months ended March 31, 2021 (“Q1 2021”), we reported consolidated net revenue of $12.6 million, representing an increase of $4.2 million from the three months ended March 31, 2020 (“Q1 2020”). This change was primarily due to:
•Continued growth of the adult-use market in Canada and sales in the Israeli medical market, partially offset by strategic price reductions on various adult-use cannabis products in Canada in the second half of 2020.
•An increase in sales in the U.S. segment in Q1 2021 compared to Q1 2020, primarily driven by the introduction of new hemp-derived CBD products.
Cost of sales and gross profit (loss) - consolidated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
$
|
15,574
|
|
|
$
|
6,946
|
|
|
$
|
8,628
|
|
|
124
|
%
|
|
Inventory write-down
|
|
|
|
|
|
|
|
|
—
|
|
|
7,962
|
|
|
(7,962)
|
|
|
(100)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
|
|
|
|
|
|
(2,963)
|
|
|
(6,476)
|
|
|
3,513
|
|
|
(54)
|
%
|
|
Gross margin
|
|
|
|
|
|
|
|
|
(23)
|
%
|
|
(77)
|
%
|
|
N/A
|
|
54
|
pp
|
For Q1 2021, we reported a consolidated gross loss of $3.0 million, representing a decrease in losses of $3.5 million from Q1 2020. This change was primarily due to:
•The increase in net revenue from Q1 2020, as described above.
•A decrease in inventory write-downs in the Rest of World (“ROW”) segment.
Adjusted EBITDA – consolidated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Adjusted EBITDA (i)
|
|
|
|
|
|
|
|
|
$
|
(37,075)
|
|
|
$
|
(37,055)
|
|
$
|
(20)
|
|
|
—
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i) See “Non-GAAP measures” for information related to Non-GAAP measures.
For Q1 2021, we reported a consolidated Adjusted EBITDA loss of $37.1 million, representing a marginal increase from Q1 2020. This was primarily due to:
•An increase in sales and marketing costs due to brand development in the U.S. segment, partially offset by a decrease in sales and marketing spend in the ROW segment.
•An increase in research and development costs primarily driven by increased spending on product development and developing cannabinoid intellectual property.
•Offsetting decreases in gross loss, as described above, and general and administrative costs.
Other items affecting the comparability of net income (loss) during Q1 2021 and Q1 2020
Interest income, net
For Q1 2021, we reported interest income, net of $2.3 million representing a decrease of $5.4 million from Q1 2020. Net interest income in the first quarter of 2021 decreased compared to the first quarter of 2020 primarily due to a lower interest earning account during the three months ended March 31, 2021 compared to the interest earning accounts during the three months ended March 31, 2020.
Gain/loss on revaluation of derivative liabilities
For Q1 2021, we reported a loss on revaluation of derivative liabilities of $116.9 million representing a decrease of $230.2 million from Q1 2020. The valuation of derivative liabilities is based on inputs such as the Company’s share price and volatility, expected term and expected risk-free interest rate which have in the past, and may in the future, fluctuate significantly period-to-period. The Company expects continued changes in derivative valuations. For further information, see Note 5. Derivative Liabilities to the Company’s condensed consolidated financial statements under Item 1 “Financial Statements” of this Quarterly Report.
Review costs related to restatement of 2019 interim financial statements
For Q1 2021, we reported review costs related to the restatement of 2019 interim financial statements of $2.0 million, which are included within general and administrative expenses in the consolidated statements of net income (loss) representing a decrease of $2.4 million from Q1 2020. These financial statement review costs include costs related to the restatement of the Company’s 2019 interim financial statements, costs related to the Company’s responses to requests for information from various regulatory authorities relating to such restatement and legal costs defending shareholder class action complaints brought against the Company as a result of the restatement.
Impairment loss on property, plant and equipment and right-of-use assets
For Q1 2021, we reported an impairment loss on property, plant and equipment of $1.0 million related to leasehold improvements located within leased premises, encompassing approximately 6,000 square feet, in Los Angeles, California, which the Company determined it no longer had plans to use. An impairment loss on the associated right-of-use asset of $0.7 million was also recorded during Q1 2021. No impairment loss was recognized on leasehold improvements or right-of-use assets during Q1 2020.
Results of Operations by Business Segment: Q1 2021 compared with Q1 2020
Summary of financial results – Rest of World (“ROW”)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Net revenue
|
|
|
|
|
|
|
|
|
$
|
10,170
|
|
|
$
|
6,256
|
|
|
$
|
3,914
|
|
|
63
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
|
|
|
|
|
|
(4,139)
|
|
|
(7,558)
|
|
|
3,419
|
|
|
(45)
|
%
|
|
Gross margin
|
|
|
|
|
|
|
|
|
(41)
|
%
|
|
(121)
|
%
|
|
N/A
|
|
80
|
pp
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA (i)
|
|
|
|
|
|
|
|
|
$
|
(22,184)
|
|
|
$
|
(29,010)
|
|
|
$
|
6,826
|
|
|
(24)
|
%
|
(i) See “Non-GAAP measures” for information related to Non-GAAP measures.
Net revenue – ROW
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Cannabis flower
|
|
|
|
|
|
|
|
|
$
|
9,434
|
|
|
$
|
2,741
|
|
|
$
|
6,693
|
|
|
244
|
%
|
|
Cannabis extracts
|
|
|
|
|
|
|
|
|
703
|
|
|
3,400
|
|
|
(2,697)
|
|
|
(79)
|
%
|
|
Other
|
|
|
|
|
|
|
|
|
33
|
|
|
115
|
|
|
(82)
|
|
|
(71)
|
%
|
|
Net revenue
|
|
|
|
|
|
|
|
|
$
|
10,170
|
|
|
$
|
6,256
|
|
|
$
|
3,914
|
|
|
63
|
%
|
For Q1 2021, the ROW segment reported net revenue of $10.2 million, representing an increase of $3.9 million from Q1 2020. This change was primarily due to:
•Continued growth of the adult-use cannabis flower market in Canada and sales in the Israeli medical cannabis market, partially offset by strategic price reductions on various adult-use cannabis products in Canada in the second half of 2020 and a decrease in cannabis extract sales in Canada primarily due to fluctuating provincial demand.
Cost of sales and gross profit (loss) – ROW
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
$
|
14,309
|
|
$
|
5,852
|
|
$
|
8,457
|
|
|
145
|
%
|
|
Inventory write-down
|
|
|
|
|
|
|
|
|
—
|
|
7,962
|
|
(7,962)
|
|
|
(100)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
|
|
|
|
|
|
(4,139)
|
|
(7,558)
|
|
3,419
|
|
|
(45)
|
%
|
|
Gross margin
|
|
|
|
|
|
|
|
|
(41)
|
%
|
|
(121)
|
%
|
|
N/A
|
|
80
|
pp
|
For Q1 2021, the ROW segment reported a gross loss of $4.1 million, representing a decrease in losses of $3.4 million from Q1 2020. This change was primarily due to:
•An increase in net revenue from Q1 2021, as described above.
•A decrease in inventory write-downs.
Adjusted EBITDA – ROW
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Adjusted EBITDA (i)
|
|
|
|
|
|
|
|
|
$
|
(22,184)
|
|
|
$
|
(29,010)
|
|
|
$
|
6,826
|
|
|
(24)
|
%
|
(i) See “Non-GAAP measures” for information related to Non-GAAP measures.
For Q1 2021, the ROW segment reported an Adjusted EBITDA loss of $22.2 million, representing a decrease in losses of $6.8 million from Q1 2020. This change was primarily due to:
•A decrease in gross loss from Q1 2020, as described above.
•A decrease in general and administrative expenses related to a decrease in professional and consulting fees.
•A partially offsetting increase in research and development costs primarily driven by increased spending on product development and developing cannabinoid intellectual property.
Summary of financial results – United States (“U.S.”)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Net revenue
|
|
|
|
|
|
|
|
|
$
|
2,441
|
|
|
$
|
2,176
|
|
|
$
|
265
|
|
|
12
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
|
|
|
|
|
|
1,176
|
|
|
1,082
|
|
|
94
|
|
|
9
|
%
|
|
Gross margin
|
|
|
|
|
|
|
|
|
48
|
%
|
|
50
|
%
|
|
N/A
|
|
(2)
|
pp
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA (i)
|
|
|
|
|
|
|
|
|
$
|
(9,510)
|
|
|
$
|
(5,782)
|
|
|
(3,728)
|
|
|
64
|
%
|
(i) See “Non-GAAP measures” for information related to Non-GAAP measures.
Net revenue – U.S.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Net revenue
|
|
|
|
|
|
|
|
|
$
|
2,441
|
|
|
$
|
2,176
|
|
|
$
|
265
|
|
|
12
|
%
|
For Q1 2021, the U.S. segment reported net revenue of $2.4 million, representing an increase of $0.3 million from Q1 2020. This change was primarily due to:
•An increase in product sales in the U.S. segment in Q1 2021 compared to Q1 2020, primarily driven by the introduction of new U.S. hemp-derived CBD products.
Cost of sales and gross profit (loss) – U.S.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
$
|
1,265
|
|
|
$
|
1,094
|
|
|
$
|
171
|
|
|
16
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
|
|
|
|
|
|
1,176
|
|
|
1,082
|
|
|
94
|
|
|
9
|
%
|
|
Gross margin
|
|
|
|
|
|
|
|
|
48
|
%
|
|
50
|
%
|
|
N/A
|
|
(2)
|
pp
|
For Q1 2021, the U.S. segment reported gross profits of $1.2 million, with gross profit margins of 48%, representing an increase of $0.1 million from Q1 2020. This change was primarily due to:
•An increase in net revenue from Q1 2020, as described above.
Adjusted EBITDA – U.S.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
|
|
For the three months ended March 31,
|
|
Change
|
|
|
|
|
|
|
|
|
|
|
2021
|
|
2020
|
|
$
|
|
%
|
|
Adjusted EBITDA (i)
|
|
|
|
|
|
|
|
|
$
|
(9,510)
|
|
|
$
|
(5,782)
|
|
|
$
|
(3,728)
|
|
|
64
|
%
|
(i) See “Non-GAAP measures” for information related to Non-GAAP measures.
For Q1 2021, the U.S. segment reported an Adjusted EBITDA loss of $9.5 million, representing an increase in losses of $3.7 million. This change was primarily due to:
•An increase in sales and marketing costs related to brand development.
Non-GAAP Measures
Cronos Group reports its financial results in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”). This Quarterly Report refers to measures not recognized under U.S. GAAP (“non-GAAP measures”). These non-GAAP measures do not have a standardized meaning prescribed by U.S. GAAP and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these non-GAAP measures are provided as a supplement to corresponding U.S. GAAP measures to provide additional information regarding the results of operations from management’s perspective. Accordingly, non-GAAP measures should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. All non-GAAP measures presented in this Quarterly Report are reconciled to their closest reported U.S. GAAP measure. Reconciliations of historical adjusted financial measures to corresponding U.S. GAAP measures are provided below.
Adjusted EBITDA
Management reviews Adjusted EBITDA, a non-GAAP measure which excludes non-cash items and items that do not reflect management’s assessment of on-going business performance. Management defines Adjusted EBITDA as net income (loss) before interest, tax expense, depreciation and amortization adjusted for: impairment loss on property, plant and equipment and right-of-use assets, loss (gain) on revaluation of derivative liabilities, other loss (income), loss from discontinued operations, share-based payments and review costs related to the restatement of the Company’s 2019 interim financial statements, the Company’s responses to the reviews of such interim financial statements by various regulatory authorities and legal costs defending shareholder class action complaints brought against the Company as a result of the restatement (see Part II, Item 1 “Legal Proceedings” of this Quarterly Report for a discussion of the regulatory reviews and shareholder class action complaints relating to the restatement of the 2019 interim financial statements).
Management believes that Adjusted EBITDA provides the most useful insight into underlying business trends and results and provides a more meaningful comparison of period-over-period results. Management uses Adjusted EBITDA for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets.
Adjusted EBITDA by segment
Management also reviews adjusted earnings (loss) before interest, tax, depreciation and amortization by segment (“Adjusted EBITDA by segment”), a non-GAAP measure which excludes non-cash items and items that do not reflect management’s assessment of on-going business performance. Corporate expenses are removed from Adjusted EBITDA by segment. Corporate expenses are expenses that relate to the consolidated business. The Company’s method of allocating corporate expenses is refined periodically. Management defines Adjusted EBITDA by segment as net income (loss) by segment before interest, tax expense, depreciation and amortization adjusted for the same items that are adjusted in consolidated Adjusted EBITDA.
Management believes that Adjusted EBITDA by segment provides useful insight into underlying segment trends and results and provides a more meaningful comparison of period-over-period segment results. Management uses Adjusted EBITDA by segment for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets.
Adjusted EBITDA and Adjusted EBITDA by segment is reconciled to net income (loss) as follows for Q1 2021 and Q1 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
|
|
For the three months ended March 31,
|
|
|
|
|
|
|
2021
|
|
2020
|
|
Net income (loss)
|
|
|
|
|
$
|
(161,625)
|
|
|
$
|
75,681
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Interest income, net
|
|
|
|
|
(2,329)
|
|
|
(7,751)
|
|
|
|
|
|
|
|
|
|
|
Impairment loss on property, plant and equipment and right-of-use assets
|
|
|
|
|
1,741
|
|
|
—
|
|
Loss (gain) on revaluation of derivative liabilities
|
|
|
|
|
116,874
|
|
|
(113,368)
|
|
Other loss
|
|
|
|
|
1,859
|
|
|
378
|
|
Loss from discontinued operations
|
|
|
|
|
21
|
|
|
—
|
|
Share-based payments
|
|
|
|
|
2,499
|
|
|
2,436
|
|
Review costs related to restatement of 2019 interim financial statements
|
|
|
|
|
2,005
|
|
|
4,407
|
|
Adjusted EBIT
|
|
|
|
|
(38,955)
|
|
|
(38,217)
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
1,880
|
|
|
1,162
|
|
Adjusted EBITDA
|
|
|
|
|
$
|
(37,075)
|
|
|
$
|
(37,055)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
Three months ended March 31, 2021
|
|
|
US
|
|
ROW
|
|
Corporate
Expenses
|
|
Total
|
|
Net income (loss)
|
$
|
(12,092)
|
|
|
$
|
(142,147)
|
|
|
$
|
(7,386)
|
|
|
$
|
(161,625)
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Interest income, net
|
(3)
|
|
|
(2,326)
|
|
|
—
|
|
|
(2,329)
|
|
|
|
|
|
|
|
|
|
|
Impairment loss on property, plant and equipment and right-of-use assets
|
1,741
|
|
|
—
|
|
|
—
|
|
|
1,741
|
|
Loss on revaluation of derivative liabilities
|
—
|
|
|
116,874
|
|
|
—
|
|
|
116,874
|
|
Other loss
|
—
|
|
|
1,859
|
|
|
—
|
|
|
1,859
|
|
Loss from discontinued operations
|
—
|
|
|
21
|
|
|
—
|
|
|
21
|
|
Share-based payments
|
745
|
|
|
1,754
|
|
|
—
|
|
|
2,499
|
|
Review costs related to restatement of 2019 interim financial statements
|
—
|
|
|
—
|
|
|
2,005
|
|
|
2,005
|
|
Adjusted EBIT
|
(9,609)
|
|
|
(23,965)
|
|
|
(5,381)
|
|
|
(38,955)
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
99
|
|
|
1,781
|
|
|
—
|
|
|
1,880
|
|
Adjusted EBITDA
|
$
|
(9,510)
|
|
|
$
|
(22,184)
|
|
|
$
|
(5,381)
|
|
|
$
|
(37,075)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
Three months ended March 31, 2020
|
|
|
US
|
|
ROW
|
|
Corporate
Expenses
|
|
Total
|
|
Net income (loss)
|
$
|
(6,516)
|
|
|
$
|
88,867
|
|
|
$
|
(6,670)
|
|
|
$
|
75,681
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Interest income, net
|
(7)
|
|
|
(7,744)
|
|
|
—
|
|
|
(7,751)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on revaluation of derivative liabilities
|
—
|
|
|
(113,368)
|
|
|
—
|
|
|
(113,368)
|
|
Other loss
|
—
|
|
|
378
|
|
|
—
|
|
|
378
|
|
|
|
|
|
|
|
|
|
|
Share-based payments
|
706
|
|
|
1,730
|
|
|
—
|
|
|
2,436
|
|
Review costs related to restatement of 2019 interim financial statements
|
—
|
|
|
—
|
|
|
4,407
|
|
|
4,407
|
|
Adjusted EBIT
|
(5,817)
|
|
|
(30,137)
|
|
|
(2,263)
|
|
|
(38,217)
|
|
Adjustments
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
35
|
|
|
1,127
|
|
|
—
|
|
|
1,162
|
|
Adjusted EBITDA
|
$
|
(5,782)
|
|
|
$
|
(29,010)
|
|
|
$
|
(2,263)
|
|
|
$
|
(37,055)
|
Liquidity and Capital Resources
As of March 31, 2021, we had $1,024.5 million in cash and cash equivalents and $214.9 million in short-term investments, which comprise the majority of the Company’s cash position. Cronos Group believes that the existing cash and cash equivalents and the short-term investments will be sufficient to fund the business operations and capital expenditures over the next twelve months.
Summary of cash flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(In thousands of U.S. dollars)
|
For the three months ended March 31,
|
|
|
2021
|
|
2020
|
|
Cash provided/(used) in operating activities
|
$
|
(46,002)
|
|
|
$
|
(38,898)
|
|
|
Cash provided/(used) in investing activities
|
(9,717)
|
|
|
59,086
|
|
|
Cash provided/(used) by financing activities
|
(9,276)
|
|
|
(448)
|
|
|
Effect of foreign currency translation on cash and cash equivalents
|
11,422
|
|
|
(91,037)
|
|
|
Net change in cash
|
$
|
(53,573)
|
|
|
$
|
(71,297)
|
|
YTD 2021 cash flows vs YTD 2020 cash flows
Operating activities
During the three months ended March 31, 2021, we used $46.0 million of cash in operating activities as compared to cash used of $38.9 million in the three months ended March 31, 2020, representing an increase in cash used of $7.1 million. This change is primarily driven by an increase in cost of sales and operating expenses, partially offset by changes in working capital during the three months ended March 31, 2021.
Investing activities
During the three months ended March 31, 2021, we used $9.7 million of cash in investing activities, compared to $59.1 million of cash provided by investing activities during the three months ended March 31, 2020, representing a decrease of $68.8 million in cash provided by investing activities. This change is primarily driven by a decrease in the net effect of the purchases of, and proceeds from the maturities of short-term investments during the three months ended March 31, 2021, due to the timing of purchases and maturities of short-term investments.
Financing activities
During the three months ended March 31, 2021, cash used in financing activities was $9.3 million, compared to $0.4 million of cash used in financing activities during the three months ended March 31, 2020, representing a decrease of $8.9 million in cash used in financing activities. This change is primarily driven by taxes withheld on share-based awards during the three months ended March 31, 2021.
Critical Accounting Policies and Estimates
The Company’s critical accounting policies and estimates are discussed in the 2020 Annual Report. There have been no material changes to these critical accounting policies and estimates.